Pacific Biosciences of California (PACB)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $611.98M
Last updated: Nov 17, 2026 at 11:06 AM ET
Pacific Biosciences of California (PACB) Stock Forecast
Analysts expect Pacific Biosciences of California (PACB) to earn -$0.49 per share in the fiscal year ending Dec 31, 2026, on revenue of $157.48M. Of 8 analysts, 4 rate the stock Buy or Strong Buy, 3 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.75, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 50% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 50.0% |
| Hold | 3 | 37.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 12.5% |
- Consensus
- Hold
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 13.1%.
- Fiscal year ending Dec 31, 2026
- -$0.49
- EPS consensus, revenue $157.48M
- Fiscal year ending Dec 31, 2027
- -$0.40
- EPS consensus, revenue $178.09M
- Next report
- Feb 9, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.49 | -$0.51 to -$0.48 | 5 | $157.48M | $156.20M to $158.80M | 7 |
| Dec 31, 2027 | -$0.40 | -$0.52 to -$0.35 | 6 | $178.09M | $171.00M to $189.00M | 7 |
Quarterly Estimates
The EPS consensus rises from -$0.13 for the quarter ending Dec 31, 2026 to -$0.10 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.13 | -$0.13 to -$0.11 | 10 | $42.55M | $38.81M to $49.35M | 10 |
| Mar 31, 2027 | -$0.10 | -$0.13 to -$0.09 | 5 | $40.62M | $38.80M to $42.29M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.51.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.49 | -$0.52 | -$0.52 | -$0.51 | -$0.51 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.40 | -$0.42 | -$0.42 | -$0.40 | -$0.40 | N/A |
| Quarter ending Mar 31, 2027 | -$0.10 | -$0.11 | -$0.11 | -$0.11 | -$0.11 | N/A |
Frequently Asked Questions About PACB
What is the PACB stock forecast?
Consensus analyst estimates put Pacific Biosciences of California's EPS at -$0.49 for the fiscal year ending Dec 31, 2026, on revenue of $157.48M. The consensus rating from 8 analysts is Hold.
How do analysts rate PACB stock?
Of 8 analysts covering Pacific Biosciences of California, 0 rate it Strong Buy, 4 Buy, 3 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from PACB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.49, with estimates from -$0.51 to -$0.48 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.40, with estimates from -$0.52 to -$0.35 from 6 analysts.
What revenue do analysts expect from Pacific Biosciences of California next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $157.48M, with estimates from $156.20M to $158.80M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $178.09M, with estimates from $171.00M to $189.00M.
How many analysts cover PACB?
8 analysts rate Pacific Biosciences of California stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PACB pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts